On the spot results to support efficient diagnosis and management of cardiovascular diseases
For Frontline Healthcare Providers, cobas h 232 POC system is a portable point-of-care system that supports optimized treatment of patients with symptoms of chest pain and dyspnea, because it enables confident on-the-spot diagnosis and assessment of the patient’s condition based on objective results, based on objective results, that can be compared with the Roche laboratory methods and shared wirelessly for immediate feedback and response.
On-the-spot results are available in 12 minutes or less1,2,3,4,5
Handheld point of care system is lightweight and easy to use, even in mobile situation6
Accurate results, aligned with Roche central laboratory tests7
Connection to the cobas® infinity POC solution helps remote management of the POC testing and quality assurance from a single location.6
The cobas h 232 POC system allows rapid and easy determination of Troponin T, NT-proBNP, D-Dimer, CK-MB and Myoglobin in different settings, like ambulances, general practitioner offices and emergency rooms.
The cobas h 232 POC system allows rapid and easy determination of Troponin T, NT-proBNP, D-Dimer, CK-MB and Myoglobin in different settings, like ambulances, general practitioner offices and emergency rooms.
| Test | Measuring range | Time to result | Clinical utility |
|---|---|---|---|
| Troponin T | 40 – 2,000 ng/L |
12 min |
Early aid in diagnosis of acute myocardial infarction and identification of patients with an elevated mortality risk1 |
| NT‑proBNP | 60 – 9,000 pg/mL |
12 min |
Aid in diagnosis of patients with suspected heart failure, in monitoring of patients with compensated left ventricular dysfunction and in the risk stratification of patients with acute coronary syndromes2 Help in the CV risk assessment of patients with T2D. Aid in the identification of patients at CV risk with T2D without known history of CV disease to optimize cardioprotective treatment Can be used to identify elderly individuals at high‐risk for atrial fibrillation2 |
| D-Dimer | 0.1 - 4.0 µg/mL | 8 min | Aid in exclusion of deep venous thrombosis and pulmonary embolism3 |
| CK-MB | 1.0 – 40 ng/mL | 12 min | Aid in diagnosis of patients with suspected AMI, assessment of the size of the infarction and detection of re-infarction4 |
| Myoglobin | 30 – 700 ng/mL |
8 min | Aid in diagnosis of patients with suspected myocardial infarction, reperfusion control5 |
AMI: Acute Myocardial Infarction; NT-proBNP: N-terminal pro b-type natriuretic peptides; POC: Point of Care; CV: Cardiovascular; T2D: Type 2 diabetes
NT-proBNP helps to early detect Type 2 Diabetes (T2D) patients at high risk of HF, regardless of previous history of cardiovascular disease.8
NT-proBNP on cobas h 232 supports the initial diagnosis of HF and the monitoring of the disease progression in out-patient settings.2,11,12
NT-proBNP testing on the cobas h 232 POC system supports rapid up-titration as shown in the STRONG-HF study13
Pre-hospital measurement of POC Troponin T allows early identification of patients at high risk of mortality and helps ensure a fast triage to the correct location.14, 15
Contact a Roche representative. Do you have questions about our products or services? We're here to help! Contact us today.
Pre-hospital measurement of POC Troponin T in low-risk suspected NSTE-ACS patients can help save healthcare costs by reducing emergency department visits.16
POC Troponin T: Roche Cardiac POC Troponin T on cobas h 232, NSTE-ACS: non-ST-segment elevation acute coronary syndrome
References
